|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present results showed that the expression of CD45 in the neoplastic plasma cells of MM patients with EMR was associated with patient prognosis independent of other prognostic factors.
|
31532009 |
2020 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The decrease tumorigenicity correlated with a "more normal" PC immunophenotype in patients with MM and correlated with CD45 expression and a stronger expression of CXCR4.
|
31534632 |
2019 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The plasma cells from the t(11;14)-positive PCNs were largely CD19-/CD45-, similar to the t(11;14)-negative PCNs and unlike the BCL-PCD plasma cells (p < .0001).
|
29214874 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Flow cytometric quantification of cPCs using five surface antigens (CD138, CD38, CD56, CD19, and CD45) is a sensitive and simple method that can be used for assessing PCM prognosis; it would allow clinical laboratories to readily adopt a risk stratification strategy based on cPC levels in PCM patients.
|
29220877 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CPCs were immuno-phenotyped using a CD38/CD56/CD45 panel and identified in 78% of patients with monoclonal gammopathy of undetermined significance (MGUS), all patients with smouldering and symptomatic multiple myeloma (MM), and none in the controls.
|
29372735 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, CD45 positivity is an adverse prognostic factor in MM patients treated with bortezomib.
|
28521480 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117.
|
25907102 |
2016 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Flow cytometric analysis with a panel of antibodies that includes CD19, CD56, CD138, CD45 and other aberrant markers commonly expressed by PCN will allow identification of clonally unrelated PCN and B-NHL in a composite neoplasm, and distinguish them from B-NHL with plasmacytic differentiation and PCN with lymphoplasmacytic morphology.
|
24395190 |
2015 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The finding that CD45(+) MM cells with an IL-6-activated JAK/STAT3 pathway are particularly sensitive to Hsp90-Is as compared to the low CD45 expressers may provide a rational basis for selection of MM patients amenable to Hsp90-I treatment.
|
23246572 |
2013 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, malignant cells strongly stained with CD138 in all the cases, whereas leukocyte common antigen and multiple myeloma 1/interferon regulatory factor 4 were completely negative, nor immunoreactivity was seen for either κ or λ light chains.
|
21334719 |
2011 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasma cell immunophenotyping by flow cytometry can aid in this distinction as by this technique the plasma cells of LPL/WM express both CD19 and CD45 whereas primary plasma cell neoplasms are CD19 or CD45 negative.
|
21454202 |
2011 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Small lymphocyte-like MM is a rare, morphologically challenging variant distinguished from B-cell lymphoma by lack of CD45 and presence of CD138 and the clinical presentation of MM.
|
20093236 |
2010 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While Gal-1 reduced the viable cell number in CD45RA(+) B cell lines, it maintained the viability of CD45(-) U266 and CD45RA(-)RO(+) ILKM3 myeloma cell lines in the synthetic medium.
|
18537967 |
2008 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that the CD45-expression renders myeloma cells competent for not only mitogenic but also apoptotic stimuli, resulting in either proliferation or apoptosis of CD45(+) myeloma cells dependently upon the circumstantial stimuli.
|
16247487 |
2006 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
We chose U266 MM cells as a study model and isolated cells into CD45+ and CD45- subpopulations.
|
14979481 |
2004 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CD45 negative phenotype could reflect the phenotype of progressive disease in relation to the intrinsic malignancy of the MM clone.
|
15136217 |
2004 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This model includes an aberrant phenotype that is annihilation rather than decline of CD45, annihilation reflecting the terminal phase of the disease and/or an aggressive presentation of MM.
|
12846811 |
2003 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also show that RANKL expressed by MPC is functional as in vitro coculture of CD38(+++)CD45(+) and CD38(+++)CD45(-) MPC subpopulations with peripheral blood mononuclear cells resulted in the formation of multinucleate, tartrate-resistant acid phosphatase-positive osteoclasts-like cells capable of forming typical resorption pits.
|
14500379 |
2003 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene and protein expression (measured by flow cytometry) correlated well for CD19, CD20, CD23, and CD138 in CLL and MM, but not for immunoglobulin light chain, CD38 and CD79b in CLL, or CD45 and CD52 in MM.
|
12804633 |
2003 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xenografting MM precursors appear to be CD34(+)CD45(low), similar to normal progenitors.
|
12374689 |
2002 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
LHGDN |
In order to clarify the difference of cellular context between CD45- and CD45+ myeloma cells, PCR-based cDNA subtraction was performed from CD45+ U-266 cells to CD45-U-266 cells.
|
12430875 |
2002 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report the constitutive expression of a functional IL-15 receptor (IL-15R) in 6 of 6 myeloma cell lines and in CD38(high)/CD45(low )plasma cells belonging to 14 of 14 patients with multiple myeloma.
|
10627470 |
2000 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, these data shed some light on the biological role of CD45 in myeloma by determining the proliferative population among myeloma cells.
|
9808582 |
1998 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clonal plasma cells or CD38+CD45-CD45(dim) cells were identified by IM or FC in 6 of 16 MGUS patients, 4 of 8 with SMM, and 11 of 15 with MM.
|
8704185 |
1996 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correlations observed between the expression of CD45, a protein tyrosine phosphatase expressed by B lymphocytes but not by plasma cells, and the expression of the IL-6 and IL-6-receptor genes (P < .0002 and P < .005, respectively) suggest that an autocrine IL-6 loop is functioning in myeloma in preplasma cells.
|
8507873 |
1993 |